دورية أكاديمية
The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis.
| العنوان: | The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis. |
|---|---|
| المؤلفون: | Xavier MS; Pós-graduação em Pesquisa Clínica em Doenças Infecciosas, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil., Araujo-Pereira M; Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, FIOCRUZ, Bahia, Brazil.; Curso de Medicina, Faculdade ZARNS, Bahia, Brazil.; Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Bahia, Brazil., de Oliveira QM; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil., Sant'Anna FM; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil., Ridolfi FM; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil., de Andrade AMS; Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Bahia, Brazil., Figueiredo MC; Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, United States., Sterling TR; Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases, Nashville, TN, United States., Gordhan BG; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa., Kana BD; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa., Andrade BB; Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, FIOCRUZ, Bahia, Brazil.; Curso de Medicina, Faculdade ZARNS, Bahia, Brazil.; Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Bahia, Brazil., Rolla VC; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil., Gomes-Silva A; Laboratório de Pesquisa Clínica em Micobacterioses, Instituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.; Laboratório Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Jun 27; Vol. 15, pp. 1357360. Date of Electronic Publication: 2024 Jun 27 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19*/immunology , COVID-19*/blood , SARS-CoV-2*/immunology , Tuberculosis, Pulmonary*/immunology , Tuberculosis, Pulmonary*/blood , Cytokines*/blood , Cytokines*/immunology, Humans ; Male ; Female ; Cross-Sectional Studies ; Adult ; Middle Aged ; Brazil/epidemiology |
| مستخلص: | Background: The impact of previous SARS-CoV-2 infection on the systemic immune response during tuberculosis (TB) disease has not been explored. Methods: An observational, cross-sectional cohort was established to evaluate the systemic immune response in persons with pulmonary tuberculosis with or without previous SARS-CoV-2 infection. Those participants were recruited in an outpatient referral clinic in Rio de Janeiro, Brazil. TB was defined as a positive Xpert-MTB/RIF Ultra and/or a positive culture of Mycobacterium tuberculosis from sputum. Stored plasma was used to perform specific serology to identify previous SARS-CoV-2 infection (TB/Prex-SCoV-2 group) and confirm the non- infection of the tuberculosis group (TB group). Plasmatic cytokine/chemokine/growth factor profiling was performed using Luminex technology. Tuberculosis severity was assessed by clinical and laboratory parameters. Participants from TB group (4.55%) and TB/Prex-SCoV-2 (0.00%) received the complete COVID-19 vaccination. Results: Among 35 participants with pulmonary TB, 22 were classified as TB/Prex-SCoV-2. The parameters associated with TB severity, together with hematologic and biochemical data were similar between the TB and TB/Prex-SCoV-2 groups. Among the signs and symptoms, fever and dyspnea were significantly more frequent in the TB group than the TB/Prex-SCoV-2 group (p < 0,05). A signature based on lower amount of plasma EGF, G-CSF, GM-CSF, IFN-α2, IL-12(p70), IL-13, IL-15, IL-17, IL-1β, IL-5, IL-7, and TNF-β was observed in the TB/Prex-SCoV-2 group. In contrast, MIP-1β was significantly higher in the TB/Prex-SCoV-2 group than the TB group. Conclusion: TB patients previously infected with SARS-CoV-2 had an immunomodulation that was associated with lower plasma concentrations of soluble factors associated with systemic inflammation. This signature was associated with a lower frequency of symptoms such as fever and dyspnea but did not reflect significant differences in TB severity parameters observed at baseline. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Xavier, Araujo-Pereira, de Oliveira, Sant’Anna, Ridolfi, de Andrade, Figueiredo, Sterling, Gordhan, Kana, Andrade, Rolla and Gomes-Silva.) |
| References: | Cytokine. 2022 Feb;150:155785. (PMID: 34933240) J Immunol. 2003 May 15;170(10):5210-8. (PMID: 12734369) Cell Rep Med. 2021 Jul 20;2(7):100354. (PMID: 34250512) Int J Infect Dis. 2023 May;130 Suppl 1:S34-S42. (PMID: 36944383) PLoS One. 2020 Jul 15;15(7):e0235488. (PMID: 32667932) Dis Markers. 2019 Oct 29;2019:7869576. (PMID: 31781307) Kekkaku. 2012 Jan;87(1):1-7. (PMID: 22416475) Sci Rep. 2022 Jun 16;12(1):10125. (PMID: 35710573) Front Immunol. 2020 Jul 23;11:1599. (PMID: 32793233) Inflammation. 2015 Apr;38(2):691-6. (PMID: 25028104) J Infect Public Health. 2022 Feb;15(2):277-288. (PMID: 35074728) Eur Respir J. 2020 Oct 1;56(4):. (PMID: 32586885) JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899) Nature. 2022 Dec;612(7941):758-763. (PMID: 36517603) Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601) Front Pediatr. 2019 Jun 25;7:233. (PMID: 31294001) Scand J Infect Dis. 2013 Apr;45(4):256-64. (PMID: 23113626) Front Microbiol. 2022 Feb 03;12:747827. (PMID: 35185809) Curr Opin Immunol. 2007 Aug;19(4):441-7. (PMID: 17702558) Nat Immunol. 2022 Feb;23(2):194-202. (PMID: 35105985) Vaccine. 2014 Dec 5;32(51):6880-6883. (PMID: 25444814) J Pathol. 2014 Nov;234(3):338-50. (PMID: 24979482) Cell. 2022 Jul 7;185(14):2434-2451.e17. (PMID: 35764089) J Clin Oncol. 1984 Mar;2(3):187-93. (PMID: 6699671) J Clin Invest. 2021 May 17;131(10):. (PMID: 33848273) Intractable Rare Dis Res. 2020 Nov;9(4):256-259. (PMID: 33139986) Front Immunol. 2022 Aug 26;13:992743. (PMID: 36090983) Eur Respir J. 2023 Nov 29;62(5):. (PMID: 37827576) Clin Microbiol Infect. 2022 Feb;28(2):202-221. (PMID: 34715347) Vaccines (Basel). 2020 Dec 01;8(4):. (PMID: 33271822) Cell. 2023 Oct 12;186(21):4597-4614.e26. (PMID: 37738970) Microbiol Spectr. 2021 Sep 3;9(1):e0034121. (PMID: 34346750) J Clin Invest. 2021 Jun 15;131(12):. (PMID: 33945513) |
| فهرسة مساهمة: | Keywords: SARS-CoV-2; disease severity; immune response; immunomodulation; previous infection; tuberculosis |
| المشرفين على المادة: | 0 (Cytokines) |
| تواريخ الأحداث: | Date Created: 20240712 Date Completed: 20240712 Latest Revision: 20240714 |
| رمز التحديث: | 20240714 |
| مُعرف محوري في PubMed: | PMC11236595 |
| DOI: | 10.3389/fimmu.2024.1357360 |
| PMID: | 38994357 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1357360 |